Results of long-term treatment with a novel mucolytic drug pulmozim in mucoviscidosis patients

Aim. To study clinical effectiveness and safety of a new mucolytic drug pul mozim (Swetzeland) adjuvant to basic therapy in mucoviscidosis patients of different age in Russia. Material and methods. 15 patients with mucoviscidosis aged 5-36 years, func tional lung capacity and FEV-1 at least 40% received pulmozim for 30 days. The drug was given in a single daily dose 2.5 mg in inhalations. The study included three stages: initial 14 days - discontinuation of all mucolytic d rugs, 30-day course of pulmozim, 14-day follow-up without pulmozin and othe r mucolytics. Results. Pulmozim in the above regimen was effective in patients with mixed and moderate mucoviscidosis. The drug facilitates respiration, improves sp utum rheology, normalizes general condition of the patient, is simple for u se, has good organoleptic properties. Conclusion. Pulmozim is an effective mucolytic drug in combined treatment o f mucoviscidosis.